Heatwurx (PCSA)
(Delayed Data from NSDQ)
$1.42 USD
0.00 (0.00%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $1.46 +0.04 (2.82%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Heatwurx Inc. [PCSA]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: Heatwurx Inc.
Industry: Medical - Drugs
2Q24 Financial Results Reported; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Heatwurx Inc.
Industry: Medical - Drugs
NGC-Cap Phase 2 Trial Clearance; New Finance Chief; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Heatwurx Inc.
Industry: Medical - Drugs
Next-Gen Capecitabine Candidate Performs in Phase 1b Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Heatwurx Inc.
Industry: Medical - Drugs
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Heatwurx Inc.
Industry: Medical - Drugs
Revitalizing Broad-Spectrum Chemotherapy; Initiating at Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Heatwurx Inc.
Industry: Medical - Drugs
|